{"classes":[{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Week 60"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.08","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"Week 72"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.\n\n0 means the worst health you can imagine.","dispersionType":"Standard Deviation","groups":[{"description":"These are the participants in the extension phase who received Pasireotide LAR","id":"OG000","title":"Pasireotide LAR Overall"}],"paramType":"MEAN","populationDescription":"Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 48, 60 & 72","title":"Extension Phase: Change From Baseline in EQ-5D-5L Index Scores","type":"SECONDARY","unitOfMeasure":"scores on a scale"}